Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin

British Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2002, Pages 304-308

  Faaij, R A ^a   Burggraaf, J ^a   Schoemaker, R C ^a   Van Amsterdam, R G M ^b   Cohen, A F ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

Antithrombotic; Fondaparinux; Interaction; Pentasaccharide; Warfarin

Indexed keywords

FONDAPARINUX; PLACEBO; SR 90107 A; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; POLYSACCHARIDES; WARFARIN;

EID: 0036380990     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01616.x     Document Type: Article

References (9)

1. Mohan Rao LV, Nordfang O, Hoang D, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/Tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/Tissue factor activity. Blood 1995; 85: 121-129.
2. Carrie D, Caranobe C, Saivin S, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY216. Blood 1994; 84: 2571-2577.
3. Hobbelen PMJ, Dinther TGV, Vogel GMT, et al. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-270.
4. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
5. Faaij RA, Griensven JMT, Schoemaker HC, et al. The effect of warfarin on the pharmacokinetics and pharmacodynamcis of napsagatran in healthy male volunteers. Eur J Clin Pharmacol 2001; 57: 25-29.
6. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: Pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987; 42: 33-41.
7. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987; 32: 165-172.
8. Toon S, Holt BL, Mullins FG, Bullingham R, Aarons L, Rowland M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990; 30: 743-750.
9. White RH, Zhou H, Romano P, Mungall D. Changes in plasma warfarin levels and variations in steady-state prothrombin times. Clin Pharmacol Ther 1995; 58: 588-593.